Loading…
Genelux Corporation is projected to rise to $3.64 by 2027, a +20% move from its current price of $3.03. GNLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.96 | $3.03 | $3.10 | +0.02% |
| Jul 14 | $2.93 | $3.03 | $3.13 | +0.05% |
| Jul 15 | $2.91 | $3.03 | $3.16 | +0.07% |
| Jul 16 | $2.90 | $3.03 | $3.18 | +0.09% |
| Jul 17 | $2.88 | $3.03 | $3.19 | +0.11% |
| Jul 18 | $2.87 | $3.03 | $3.21 | +0.14% |
| Jul 19 | $2.86 | $3.03 | $3.23 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.86 | $3.03 | $3.23 | +0.16% |
| Week 2 | $2.79 | $3.04 | $3.31 | +0.32% |
| Week 3 | $2.74 | $3.04 | $3.38 | +0.48% |
| Week 4 | $2.70 | $3.05 | $3.44 | +0.64% |
| Week 5 | $2.67 | $3.05 | $3.50 | +0.80% |
| Week 6 | $2.63 | $3.06 | $3.55 | +0.96% |
| Week 7 | $2.61 | $3.06 | $3.60 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Genelux Corporation is a healthcare company at the clinical stage that focuses on developing oncolytic viral immunotherapies for patients with aggressive and/or difficult-to-treat solid tumors. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. Genelux also offers CHOICE, a technology and discovery and development platform, and has developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux combines its clinical-stage pipeline with its discovery platform to advance therapies for difficult-to-treat solid tumors. The strategic focus includes leveraging its Olvi-Vec program and related VACV-based candidates within its portfolio, alongside its CHOICE platform to enable ongoing development efforts. Westlake Village, California serves as Genelux’s corporate base of operations after its incorporation in 2001.
Genelux Corporation (GNLX) currently trades at $2.92 and has a market capitalization of $130.93M. The stock is ranked 3833 in its market-cap tier. These figures position Genelux as a smaller-cap biopharma name with a focused oncolytic viral therapy program targeting ovarian cancer and other solid tumors.
The price outlook from the provided forecasts suggests a bullish path beginning after 2026, with the average price rising from $2.92 in 2026 to $5.07 in 2030 and continuing to higher levels through 2050. The implied returns (ROI) expand markedly over time, culminating in a 2050 average of $34.07 and a max of $63.15.
Forecasts show a progressive, bullish trajectory for Genelux across the coming years, with the average price climbing and strong ROI figures, reflecting growing investor expectations for its OVli-Vec and VACV platform-based candidates. These projections are estimates and not guarantees of future performance.
A major floor 24.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 6.2% above — clearing it would confirm fresh momentum.
Key GNLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GNLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.99 | Buy | $2.99 | Buy |
| MA 10 | $2.96 | Buy | $2.97 | Buy |
| MA 20 | $2.95 | Buy | $2.96 | Buy |
| MA 50 | $2.93 | Buy | $2.92 | Buy |
| MA 100 | $2.79 | Buy | $2.99 | Buy |
| MA 200 | $3.67 | Sell | $3.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.47 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 106.10 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 3.77 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 52.84 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.00 | Buy |
| ADX (14) | 6.91 | Neutral |
| ATR (14) | 0.06 | Info |
In the near term, the sentiment is NEUTRAL, with RSI14 at 50 and moving averages near the price. The SMA50 is $2.85 and the SMA200 is $3.73, indicating the price sits between short- and long-term trend lines.
Key support sits at $2.80 and resistance at $3.19, shaping the immediate trade range. The 30-day price range spans from a low of $2.44 to a high of $3.50, underscoring modest near-term volatility around Genelux’s current level. Annualized volatility sits at 50.
These technical markers suggest a cautious near-term posture, with limited downside protection near $2.80 and a potential move toward the $3.19 resistance if buyers regain momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.30 | $3.03 | $4.01 | 0% | Neutral | |
| $2.94 | $3.64 | $4.74 | +20% | Bullish | |
| $3.33 | $4.22 | $5.67 | +39% | Bullish | |
| $3.46 | $4.47 | $6.17 | +48% | Bullish | |
| $3.69 | $4.85 | $6.83 | +60% | Bullish | |
| $4.66 | $6.21 | $8.91 | +105% | Bullish | |
| $5.35 | $7.24 | $10.56 | +139% | Bullish | |
| $5.88 | $8.06 | $11.94 | +166% | Bullish | |
| $6.53 | $9.07 | $13.62 | +199% | Bullish | |
| $6.54 | $9.19 | $13.98 | +203% | Bullish | |
| $10.91 | $16.17 | $25.98 | +434% | Bullish | |
| $17.89 | $29.04 | $50.55 | +858% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.30 | $3.03 | $3.68 | +0.00% |
| August 2026 | $2.63 | $3.09 | $3.73 | +2.12% |
| September 2026 | $2.62 | $3.09 | $3.76 | -0.03% |
| October 2026 | $2.69 | $3.20 | $3.91 | +3.30% |
| November 2026 | $2.72 | $3.25 | $4.01 | +1.76% |
| December 2026 | $2.70 | $3.23 | $4.01 | -0.56% |
Click any year to see its month-by-month GNLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GNLX price prediction for 2026 points to an average of $3.03 (low $2.30, high $4.01) — a potential gain of 0% on today's $3.03. Price action looks broadly range-bound.
In 2027, GNLX is projected to trade between $2.94 and $4.74, averaging $3.64 — a potential gain of +20% from today's $3.03. That is up +20% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Genelux Corporation's 2028 outlook centres on $4.22, within a $3.33 to $5.67 range. That is up +16% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, GNLX could reach as high as $6.17, with a base case around $4.47 and support toward $3.46 — roughly +48% from $3.03. Buyers look set to stay in control over this stretch.
Expect GNLX to range from $3.69 to $6.83 through 2030. The $4.85 average target implies a +60% move from current prices. That is up +8% on the projected 2029 average. Momentum favours further upside here.
The GNLX price prediction for 2031 points to an average of $6.21 (low $4.66, high $8.91) — a potential gain of +105% on today's $3.03. Buyers look set to stay in control over this stretch.
In 2032, GNLX is projected to trade between $5.35 and $10.56, averaging $7.24 — a potential gain of +139% from today's $3.03. That is up +17% on the projected 2031 average. Momentum favours further upside here.
Genelux Corporation's 2033 outlook centres on $8.06, within a $5.88 to $11.94 range. That is up +11% on the projected 2032 average. That marks a +166% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, GNLX could reach as high as $13.62, with a base case around $9.07 and support toward $6.53 — roughly +199% from $3.03. Momentum favours further upside here.
Expect GNLX to range from $6.54 to $13.98 through 2035. The $9.19 average target implies a +203% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The GNLX price prediction for 2040 points to an average of $16.17 (low $10.91, high $25.98) — a potential gain of +434% on today's $3.03. Momentum favours further upside here.
In 2050, GNLX is projected to trade between $17.89 and $50.55, averaging $29.04 — a potential gain of +858% from today's $3.03. That is up +80% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GNLX today (≈ 330.033003 GNLX) could be worth
$9,584.4
+$8,584.4 (+858%) by 2050 · US Dollar
Based on the average projected GNLX price of $29.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GNLXwould be worth at today's price.
$1,000 invested in GNLX on Jul 10, 2025 (≈ 290.69767 GNLX) would be worth
$880.81
-$119.19 (-11.9%) today · 0.88× · US Dollar
Based on a GNLX entry price of $3.44 vs. today's $3.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.99 | $1,013.38 | +1.3% |
| 1 month ago | $2.86 | $1,059.44 | +5.9% |
| 3 months ago | $2.54 | $1,192.91 | +19.3% |
| 6 months ago | $2.65 | $1,143.4 | +14.3% |
| 1 year ago | $3.44 | $880.81 | -11.9% |
| All time (3.5y) ago | $6.15 | $492.68 | -50.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GNLX forecast.
Our base-case forecast reaches $6.10 around 2031.
Implied market cap at $6.10: $273.53M
The multi-year forecast shows Genelux moving into a clearly bullish regime after 2026. In 2026 the avg price is $2.92 with a 0 ROI, turning more bullish thereafter: 2027 avg $3.68, 2028 avg $4.14, 2029 avg $4.50, 2030 avg $5.07, and 2031 avg $6.59. The path continues to 2032 avg $7.88, 2033 avg $8.86, 2034 avg $9.89, and 2035 avg $10.11, all with bullish sentiment.
Looking further out, Genelux’s forecast shows substantial upside: 2040 avg $18.48 (ROI 532.9) and 2050 avg $34.07 (ROI 1066.7), with a max of $31.30 in 2040 and $63.15 in 2050. The long-term sentiment remains BULLISH through 2050, reflecting a strong carry of growth expectations for Olvi-Vec and related VACV-based candidates, albeit with inherent uncertainty in such projections.
Tap a question to reveal the answer.
2030: min $3.75, avg $5.07, max $7.39, ROI 73.6, sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with rising averages and ROI: 2027 avg $3.68, 2028 avg $4.14, 2029 avg $4.50, 2030 avg $5.07 (ROI 73.6). The outlook remains bullish through 2050, but these are estimates, not guarantees.
The 2050 max forecast is $63.15, with a 2050 avg of $34.07 and ROI 1066.7, indicating a potential to approach or exceed $60 on the upside of the forecast, subject to uncertainty.
Current price is $2.92 and market cap is $130.93M.
RSI14 is 50, SMA50 is $2.85, SMA200 is $3.73. Support is at $2.80 and resistance at $3.19. The 30-day range is $2.44 to $3.50, and annualized volatility is 50.
Genelux Corporation Community Discussion
0Share your Genelux Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.